http://rayandmave.wordpress.com/ updated Blog as Im doing well on the trial for Mesothelioma

Less than one minute read time.

http://rayandmave.wordpress.com/

Phase III trial, expecting to enrol 400 adult patients affected by malignant pleural mesothelioma with disease progressing after a pemetrexed-based chemotherapy. The trial investigates the administration of NGR-hTNF plus best investigator’s choice (BIC) versus placebo plus BIC, where BIC includes either supportive care alone or combined with one chemotherapeutic agent (either doxorubicin, or gemcitabine, or vinorelbine). Randomisation ratio will be 1:1. Before randomisation, investigators decide for each patient if he/she is candidate to either supportive care alone or combined with chemotherapy; patients are then randomly assigned to either of the two treatment arms by specific stratification factors. NGR-hTNF is given intravenously as 1-hour infusion at 0.8 µg/m2 once a week, until disease progression; placebo follows the same administration schedule in the control arm. BIC is delivered, where applicable and as appropriate, according to Institutional and literature guidelines, and chemotherapy is administered as per standard clinical practice. The primary endpoint of the trial is overall survival. Secondary endpoints include progression-free survival, disease control rate, safety, and patient quality of life. http://www.mesotheliomacenter.org/mesothelioma-news/2010/04/20/molmed-starts-phase-iii-trial-of-ngr-htnf-in-mesothelioma/

Anonymous